Mutations inSETBP1are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression-Reference-Cited by-同舟云学术

Mutations inSETBP1are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression

Published:2013-07 Issue: Volume: Page:n/a-n/a
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Fernandez-Mercado Marta¹,Pellagatti Andrea¹,Di Genua Cristina¹,Larrayoz Maria Jose²,Winkelmann Nils³,Aranaz Paula,Burns Adam⁴,Schuh Anna⁴,Calasanz Maria Jose²,Cross Nicholas C. P.,Boultwood Jacqueline¹

Affiliation:

1. LLR Molecular Haematology Unit; NDCLS; RDM; John Radcliffe Hospital; Oxford; UK

2. Department of Genetics; University of Navarra; Pamplona; Spain

3. National Genetics Reference Laboratory; Salisbury NHS Foundation Trust; Salisbury; UK

4. NIHR Biomedical Research Centre; University of Oxford; Oxford; UK

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12491/fullpdf

Reference15 articles.

1. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia;Cristobal;Blood,2010

2. Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia;Cristobal;Haematologica,2012

3. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias;Damm;Leukemia,2013

4. Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics;Fernandez-Mercado;PLoS ONE,2012

5. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype;Grossmann;Blood,2011

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The m6A methyltransferase METTL14 promotes cell proliferation via SETBP1-mediated activation of PI3K-AKT signaling pathway in myelodysplastic neoplasms;Leukemia;2024-07-25

2. Establishment and validation of a gene mutation-based risk model for predicting prognosis and therapy response in acute myeloid leukemia;Heliyon;2024-05

3. Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition;European Journal of Haematology;2023-07-27

4. Thirty years of SET/TAF1β/I2PP2A: from the identification of the biological functions to its implications in cancer and Alzheimer’s disease;Bioscience Reports;2022-11

5. The genetics of myelodysplastic syndromes and the opportunities for tailored treatments;Frontiers in Oncology;2022-10-20